A secretory leukocyte protease inhibitor variant with improved activity against lung infection

Mucosal Immunology

Volumn 9, Issue 3, 2016, Pages 669-676

  Camper, N ^a   Glasgow, A M A ^a   Osbourn, M ^a   Quinn, D J ^a   Small, D M ^a   McLean, D T ^a   Lundy, F T ^a   Elborn, J S ^a   McNally, P ^b   Ingram, R J ^a   Weldon, S ^a   Taggart, C C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOCYTE ELASTASE INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR A16G; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR S15G A16G; UNCLASSIFIED DRUG; LEUKOCYTE ELASTASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SLPI PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFICACY; ENZYME INHIBITOR INTERACTION; HUMAN; LUNG INFECTION; MOLECULAR STABILITY; MOUSE; MURINE MODEL; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PSEUDOMONAS INFECTION; SITE DIRECTED MUTAGENESIS; SPUTUM CULTURE; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; LUNG; METABOLISM; MICROBIOLOGY; MUTATION; NEUTROPHIL CHEMOTAXIS; PSEUDOMONAS AERUGINOSA;

ANIMALS; CELLS, CULTURED; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; LEUKOCYTE ELASTASE; LUNG; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEUTROPHIL INFILTRATION; PROTEOLYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 84964940354     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.90     Document Type: Article

References (33)

1. Chmiel, J.F., Berger, M. & Konstan, M.W. The role of inflammation in the pathophysiology of CF lung disease. Clin. Rev. Allergy Immunol. 23, 5-27 (2002).
2. Downey, D.G.,Bell, S.C. & Elborn, J.S.Neutrophils in cystic fibrosis. Thorax 64, 81-88 (2009).
3. Mayer-Hamblett, N. et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 822-828 (2007).
4. Murray, T.S., Egan, M. & Kazmierczak, B.I. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19, 83-88 (2007).
5. Courtney, J.M., Ennis, M. & Elborn, J.S. Cytokines and inflammatory mediators in cystic fibrosis. J. Cyst. Fibros. 3, 223-231 (2004).
6. Van Der Vliet, A. et al. Myeloperoxidase and protein oxidation in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L537-L546 (2000).
7. Voynow, J.A., Fischer,B.M. & Zheng, S. Proteases and cystic fibrosis. Int. J. Biochem. Cell Biol. 40, 1238-1245 (2008).
8. Sly, P.D. et al. Risk factors for bronchiectasis in children with cystic fibrosis. N. Engl. J. Med. 368, 1963-1970 (2013).
9. Sagel, S.D., Wagner, B.D., Anthony, M.M., Emmett, P. & Zemanick, E.T. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 186, 857-865 (2012).
10. Weldon, S. et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J. Immunol. 183, 8148-8156 (2009).
11. Guyot, N. et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J. Biol. Chem. 283, 32377-32385 (2008).
12. Rees, D.D.,Brain, J.D.,Wohl, M.E.,Humes, J.L. & Mumford,R.A. Inhibition of neutrophil elastase in CFsputumby L-658,758. J. Pharmacol. Exp. Ther. 283, 1201-1206 (1997).
13. Attucci, S. et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J. Pharmacol. Exp. Ther. 318, 803-809 (2006).
14. Dunlevy, F.K., Martin, S.L., de Courcey, F., Elborn, J.S. & Ennis, M. Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. J. Cyst. Fibros. 11, 300-304 (2012).
15. Scott, A., Weldon, S. & Taggart, C.C. SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem. Soc. Trans. 39, 1437-1440 (2011).
16. Sallenave, J.-M. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am. J. Respir. Cell Mol. Biol. 42, 635-643 (2010).
17. Bingle, C.D. & Vyakarnam, A. Novel innate immune functions of the whey acidic protein family. Trends Immunol. 29, 444-453 (2008).
18. Moreau, T. et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90, 284-295 (2008).
19. Taggart, C.C., Greene, C.M., Carroll, T.P., O'Neill, S.J. & McElvaney, N.G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.Am. J.Respir.Crit.CareMed. 171, 1070-1076 (2005).
20. Greene, C.M. & McElvaney, N.G. Proteases and antiproteases in chronic neutrophilic lung disease-relevance to drug discovery. Br. J. Pharmacol. 158, 1048-1058 (2009).
21. Thompson, R.C. & Ohlsson, K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. US. 83, 6692-6696 (1986).
22. Krowarsch, D., Cierpicki, T., Jelen, F. & Otlewski, J. Canonical protein inhibitors of serine proteases. Cell. Mol. Life Sci. 60, 2427-2444 (2003).
23. Markert, Y., Köditz, J., Mansfeld, J., Arnold, U. & Ulbrich-Hofmann, R. Increased proteolytic resistance of ribonuclease A by protein engineering. Protein Eng. 14, 791-796 (2001).
24. Rawlings, N.D., Barrett, A.J. & Bateman, A. MEROPS: The database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 40, D343-D350 (2012).
25. Taggart, C.C. et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 202, 1659-1668 (2005).
26. Hiemstra, P.S. et al. Antibacterial activity of antileukoprotease. Infect. Immun. 64, 4520-4524 (1996).
27. McElvaney, N.G. et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest. 90, 1296-1301 (1992).
28. Maus, U. et al. The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am. J. Respir. Crit. Care Med. 166, 268-273 (2002).
29. Maus, U., Huwe, J., Maus, R.,Seeger,W. & Lohmeyer, J. Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am. J. Respir. Crit. Care Med. 164, 406-411 (2001).
30. Small, D.M. et al. A functional variant of elafin with improved antiinflammatory activity for pulmonary inflammation. Mol. Ther. 23, 24-31 (2014).
31. Mall, M., Grubb, B.R., Harkema, J.R., O'Neal, W.K. & Boucher, R.C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10, 487-493 (2004).
32. Wiedow, O., Harder, J., Bartels, J., Streit, V. & Christophers, E. Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. Biochem. Biophys. Res. Commun. 248, 904-909 (1998).
33. McLean, D.T.F., Lundy, F.T. & Timson, D.J. IQ-motif peptides as novel anti-microbial agents. Biochimie 95, 875-880 (2013).